

Trial Tracker is a web-based dashboard that visualizes participant accrual across active USC research studies. Charts and metrics are derived directly from OnCore data and is updated nightly.

Key Chart Components

Expected Accrual Line: Represents the ideal pace of recruitment required to meet your total accrual goal within the designated recruitment period.

Actual Accrual Line: Displays the number of participants accrued to the study based on the following statuses in OnCore:

- ELIGIBLE
- ON STUDY
- ON TREATMENT
- ON FOLLOW UP
- ELIGIBLE(O)
- OFF STUDY
- OFF TREATMENT

Projected Accrual Line: If the recruitment period is still ongoing, this line estimates future accrual based on the last 3 months of recruitment activity.

Consented Accrual Line: Shows the total amount of participants who have consented to participate. This includes the following statuses in OnCore:

- CONSENTED
- ON STUDY
- NOT ELIGIBLE
- OFF STUDY
- ELIGIBLE
- ON FOLLOW UP
- OFF TREATMENT
- ELIGIBLE(O)
- ON TREATMENT
- WITHDRAWN

Accrual Statistic:

Are calculated based on OnCore data and the adjusted recruitment period. These are shown as:

- Expected Enrollment by Now
- Expected enrollment per Month
- Actual Enrollment by Now
- Actual Enrollment per Month

Dash Indicators:

- **Yellow Status:** Study has accrued 60-89% of its expected enrollment as of today.
- **Red Status:** Study has accrued less than 60% of its expected enrollment.

Recruitment Period Logic

★ PC Console

Protocol No.: CTSU-EA8212

Library: Oncology

PI: Daneshmand, Sia

Sponsor: ECOG-ACRIN

Protocol Target Accrual: 800

Accrual To Date: 27

Protocol Status: CLOSED TO ACCRUAL

RC Total Accrual Goal (Upper): 25

IRB Expiration: 05/14/2026

Select Protocol

CTSU-EA8212

Details

Management

Staff

Sponsor

IND/IDE

ClinicalTrials.gov / CTRP

Main

Treatment

Institution

Accrual

Status

Reviews

Documents/Info

Eligibility

Protocol Calendar

Conclusions

Annotations

Deviations

New Protocol

Protocol Details

Protocol No.	CTSU-EA8212	NCT Number	NCT05538663
Library	Oncology	Department	UROLOGY
Organizational Unit	USC Oncology		
Title	A Randomized Phase III Trial of Intravesical BCG versus Intravesical Docetaxel and Gemcitabine Treatment in BCG Naïve High Grade Non-Muscle Invasive Bladder Cancer (BRIDGE)		
Short Title	Rand/ Ph III Trial of Intravesical BCG vs Intravesical GEMDOCE Tx in BCG Naïve High Grade NMIBC (BRI)		
Objectives			
Phase	III	Scope	Age Adults
Drug Accountability	Investigator Initiated Protocol	No	Consent at Age of Majority N/A
Open For Affiliates Only	Summary Accrual Info. Only		Exclude Protocol on Web No
Cancer Control	Cancer Prevention		Protocol Type Treatment (Therapeutic)
Registration Center	Involves Correlates or Companions		Data Table 4 Report Type Interventional
Includes Specimen Banking?	No	Companion Study? No	Data Monitoring
Precision Trial	Precision Trial Classification		Adjuvant
Rare Disease	Certificate(s) of Confidentiality		Multi-site Trial
			Pilot
			Investigational Drug N/A
			Investigational Device N/A
			Pragmatic Trial

Accrual Information

Protocol Target Accrual	800	RC Total Accrual Goal (Lower)	RC Total Accrual Goal (Upper)	25
RC Annual Accrual Goal		Affiliate Accrual Goal	Accrual Duration (Months)	36

Completion Dates

Primary Completion Date	10/04/2026 (Anticipated)
Study Completion Date	

- Recruitment Dates (Start/End) are estimated using the Primary Completion Date and Accrual Duration (see above).
- Accrual target/goal is obtained from the RC Total Accrual Goal (Upper).
- If the enrollment occurs outside the estimated window, the chart is extended to reflect actual data.

If you notice any issues with Trial Tracker, please contact us at: crs@sc-ctsi.org.